US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
MSTR
$160.01
▲+0.00%
ASML
$1,867.31
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
MSTR
$160.01
▲+0.00%
ASML
$1,867.31
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by MorphoSys AG
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
July 12, 2024
From
MorphoSys AG
Via
Business Wire
Tickers
MOR
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
June 20, 2024
From
MorphoSys AG
Via
Business Wire
Tickers
MOR
MorphoSys AG Reports First Quarter 2024 Financial Results
April 29, 2024
From
MorphoSys AG
Via
Business Wire
Tickers
MOR
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
April 11, 2024
From
MorphoSys AG
Via
Business Wire
Tickers
MOR
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 13, 2024
From
MorphoSys AG
Via
Business Wire
Tickers
MOR
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
December 10, 2023
From
MorphoSys AG
Via
Business Wire
Tickers
MOR
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
November 20, 2023
From
MorphoSys AG
Via
Business Wire
Tickers
MOR
MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
November 15, 2023
From
MorphoSys AG
Via
Business Wire
Tickers
MOR
MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results
August 09, 2023
From
MorphoSys AG
Via
Business Wire
Tickers
MOR
MorphoSys AG Reports First Quarter 2023 Financial Results
May 03, 2023
From
MorphoSys AG
Via
Business Wire
Tickers
MOR
MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 15, 2023
From
MorphoSys AG
Via
Business Wire
Tickers
MOR
MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
November 16, 2022
From
MorphoSys AG
Via
Business Wire
Tickers
MOR
MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte Peters
August 31, 2022
From
MorphoSys AG
Via
Business Wire
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
August 03, 2022
From
MorphoSys AG
Via
Business Wire
Tickers
MOR
MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
July 28, 2022
From
MorphoSys AG
Via
AccessWire
Tickers
MOR
MPSYF
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
July 26, 2022
From
MorphoSys AG
Via
AccessWire
Tickers
MOR
MPSYF
MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
July 26, 2022
From
MorphoSys AG
Via
AccessWire
Tickers
MOR
MPSYF
MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
June 14, 2022
From
MorphoSys AG
Via
Business Wire
Tickers
MOR
MorphoSys AG Reports Outcome of Annual General Meeting 2022
May 18, 2022
From
MorphoSys AG
Via
AccessWire
Tickers
MOR
MorphoSys AG Reports First Quarter 2022 Financial Results
May 04, 2022
From
MorphoSys AG
Via
Business Wire
Tickers
MOR
Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
April 28, 2022
From
MorphoSys AG
Via
AccessWire
Tickers
MOR
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
March 22, 2022
From
MorphoSys AG
Via
AccessWire
Tickers
MOR
MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 16, 2022
From
MorphoSys AG
Via
Business Wire
Tickers
MOR
National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in Its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
March 15, 2022
From
MorphoSys AG
Via
AccessWire
Tickers
MOR
Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
March 10, 2022
From
MorphoSys AG
Via
AccessWire
Tickers
MOR
MorphoSys AG Reports Non-Cash Impairment Charge of € 231 Million on Goodwill After Consolidation of Research and Discovery Functions; Corresponding Increase of Group Operating Expenses in 2021
March 10, 2022
From
MorphoSys AG
Via
AccessWire
Tickers
MOR
MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report
January 24, 2022
From
MorphoSys AG
Via
AccessWire
Tickers
MOR
MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
January 18, 2022
From
MorphoSys AG
Via
AccessWire
Tickers
MOR
MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
January 10, 2022
From
MorphoSys AG
Via
AccessWire
Tickers
MOR
MorphoSys Presents Latest Data from the Phase 2 MANIFEST Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis
December 12, 2021
From
MorphoSys AG
Via
AccessWire
Tickers
MOR
